ライフサイエンスコーパス: protease-activated receptor

1 redefines the concept of what constitutes a protease-activated receptor.

2 endothelial cell protein C receptor but not protease activated receptors.

3 r stimulation of metabotropic purinergic and protease-activated receptors.

4 , neurogenesis and brain repair were lost in protease activated receptor 1 (PAR1) deficient mice.

5 Here we demonstrate Protease Activated Receptor 1 (PAR1) is an important reg

6 et age (IPF, FSC) and activation through the protease activated receptor 1 (PAR1) thrombin receptor (

7 -out of the thrombin receptor, also known as Protease Activated Receptor 1 (PAR1), accelerates myelin

8 us-encoded glycoprotein C (gC) can stimulate protease activated receptor 1 (PAR1)-enhanced infection

9 nt to the blood via two pathways mediated by protease activated receptor 1 (PAR1).

10 he endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR1).

11 rmeability induced by the thrombin receptor, protease activated receptor 1 (PAR1).

12 nced signaling through the G-protein coupled protease activated receptor 1 (PAR1).

13 Zn(2+) enhanced APC-mediated activation of protease activated receptor 1 and p44/42 MAPK.

14 g to several Gq-coupled receptors, including protease activated receptor 1, muscarinic acetylcholine

15 dependent stimulation of the MAPK pathway by protease activated receptor 1.

16 rating factor Xa for thrombin generation and protease activated receptor 1/2 heterodimer signaling.

17 ing activities mediated by the activation of protease-activated receptor 1 (F2R, also known as PAR1)

18 FLD, we tested whether the thrombin receptor protease-activated receptor 1 (PAR-1) and hematopoietic

19 previously reported that thrombin activates protease-activated receptor 1 (PAR-1) and induces a myof

20 epidermal growth factor receptor (EGFR) and protease-activated receptor 1 (PAR-1) in endothelial cel

21 ion of thrombin is mediated by activation of protease-activated receptor 1 (PAR-1).

22 ized to promote inflammation via cleavage of protease-activated receptor 1 (PAR1) and PAR2.

23 WT APC can potentially cleave protease-activated receptor 1 (PAR1) at Arg41 or Arg46,

24 Activation of protease-activated receptor 1 (PAR1) by activated protei

25 following the activation of the cell surface protease-activated receptor 1 (PAR1) by thrombin.

26 -1 has been shown to cleave and activate the protease-activated receptor 1 (PAR1) in noncardiac cells

27 Protease-activated receptor 1 (PAR1) is a G protein-coup

28 The G-protein coupled, protease-activated receptor 1 (PAR1) is a membrane prote

29 Protease-activated receptor 1 (PAR1) is a thrombin-activ

30 The G protein-coupled protease-activated receptor 1 (PAR1) is irreversibly pro

31 Protease-activated receptor 1 (PAR1) is the prototypical

32 cGVHD was mediated by a biased signaling of protease-activated receptor 1 (PAR1) on T lymphocytes.

33 they disrupt signaling through the platelet protease-activated receptor 1 (PAR1) receptor.

34 using variants of human APC with or without protease-activated receptor 1 (PAR1) signaling function

35 of thrombin, and is associated with altered protease-activated receptor 1 (PAR1) signaling, as PAR1

36 t protease that initiates cell signaling via protease-activated receptor 1 (PAR1) to regulate vascula

37 We found that protease-activated receptor 1 (PAR1) was transiently ind

38 We previously showed that protease-activated receptor 1 (PAR1), a G protein-couple

39 Protease-activated receptor 1 (PAR1), a G-protein couple

40 Protease-activated receptor 1 (PAR1), a thrombin-respons

41 by cleaving its G-protein-coupled receptors, protease-activated receptor 1 (PAR1), PAR4, or both.

42 CFs express 190 GPCRs and that activation of protease-activated receptor 1 (PAR1), the most highly ex

43 othelial cytoprotective actions that require protease-activated receptor 1 (PAR1), whereas thrombin a

44 gests that CXCR4 activation reduces thrombin/protease-activated receptor 1 (PAR1)-induced impairment

45 coagulation cascade and a potent trigger of protease-activated receptor 1 (PAR1)-mediated platelet a

46 d receptor 4 in human podocytes, and between protease-activated receptor 1 and protease-activated rec

47 otease-activated receptor 4, and between rat protease-activated receptor 1 and protease-activated rec

48 These data show promise for protease-activated receptor 1 antagonism in patients und

49 population with symptomatic PAD and whether protease-activated receptor 1 antagonism with vorapaxar

50 gonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets.

51 tory of myocardial infarction, inhibition of protease-activated receptor 1 with vorapaxar reduces the

52 FXa as potent, direct agonist of the PAR-1 (protease-activated receptor 1), leading to platelet acti

53 Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for

54 Mouse embryos lacking protease-activated receptors 1 and 2 showed defective hi

55 tion by thrombin and tryptase is mediated by protease-activated receptors 1 and 2, respectively.

56 s and gene expression profiles by activating protease-activated receptors 1 and 3.

57 activates platelets by binding and cleaving protease-activated receptors 1 and 4 (PAR1 and PAR4).

58 telets revealed that DXA3 formation requires protease-activated receptors 1 and 4, cytosolic phosphol

59 Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that in

60 actor (TF)-dependent thrombin generation and protease activated receptor-1 (PAR-1) activation contrib

61 The thrombin receptor protease activated receptor-1 (PAR-1) is overexpressed i

62 to generate sickle mice deficient in either protease activated receptor-1 (PAR-1) or protease activa

63 hibition of the principal thrombin receptor, protease activated receptor-1 (PAR-1), as well as defici

64 is response was dependent upon activation of protease activated receptor-1 (PAR-1).

65 Protease activated receptor-1 (PAR1) activation by throm

66 R on endothelial cells, activates endogenous protease activated receptor-1 (PAR1) and induces PAR1-me

67 pose that APC-mediated signaling through the protease activated receptor-1 (PAR1) can favorably regul

68 enase and activator of the G protein-coupled protease activated receptor-1 (PAR1), is an emerging new

69 toprotective signaling through activation of protease activated receptor-1 (PAR1).

70 l cell protein C receptor (EPCR, PROCR), and protease activated receptor-1 (PAR1, F2R) on the growth

71 Deficiency in the thrombin receptor protease activated receptor-1 reduces hepatic inflammati

72 fferences at the transcript level, including protease activated receptor-1, protease activated recept

73 Protease activated receptor-1, the presumptive thrombin

74 by proteolytic cleavage on activation of the protease activated receptor-1, with antiangiogenic prope

75 Protease-activated receptor-1 (PAR(1)) is a G-protein-co

76 eruli, aPC preserves endothelial cells via a protease-activated receptor-1 (PAR-1) and endothelial pr

77 wo targets of thrombin-mediated proteolysis, protease-activated receptor-1 (PAR-1) expressed by strom

78 Protease-activated receptor-1 (PAR-1) was localized to a

79 Tissue factor (TF) and protease-activated receptor-1 (PAR-1) were highly expres

80 eceptor for thrombin on endothelial cells is protease-activated receptor-1 (PAR-1), a member of the G

81 sed a selective agonist (TFLLR-NH(2)) of the protease-activated receptor-1 (PAR-1), a thrombin recept

82 The thrombin receptor, protease-activated receptor-1 (PAR-1), plays a key role

83 phorylation on serine residues and prevented protease-activated receptor-1 (PAR-1)-induced Ca(2+) ent

84 c kidney 293 cells through the activation of protease-activated receptor-1 (PAR-1).

85 signaling function of aPC, mediated through protease-activated receptor-1 (PAR1) and endothelial pro

86 Protease-activated receptor-1 (PAR1) contains five N-lin

87 Protease-activated receptor-1 (PAR1) couples the coagula

88 Protease-activated receptor-1 (PAR1) has been shown to p

89 rect oncogenic activity by signaling through protease-activated receptor-1 (PAR1) in carcinoma cells;

90 lood, Aisiku et al describe a novel class of protease-activated receptor-1 (PAR1) inhibitors that blo

91 Protease-activated receptor-1 (PAR1) is a G protein-coup

92 Protease-activated receptor-1 (PAR1) is a G protein-coup

93 Protease-activated receptor-1 (PAR1) is a G protein-coup

94 Protease-activated receptor-1 (PAR1) is a G protein-coup

95 Protease-activated receptor-1 (PAR1) is a G-protein-coup

96 Protease-activated receptor-1 (PAR1) is a guanine nucleo

97 activation of the G protein-coupled receptor protease-activated receptor-1 (PAR1) is an important sti

98 and thermodynamic parameters for individual protease-activated receptor-1 (PAR1) molecules in the ab

99 Contrary to this view, we show that protease-activated receptor-1 (PAR1) promotes contrastin

100 procoagulant protease, cleaves and activates protease-activated receptor-1 (PAR1) to promote inflamma

101 llular (i3) loop agonist, pepducin, based on protease-activated receptor-1 (PAR1) was solved by NMR a

102 This is exemplified by protease-activated receptor-1 (PAR1), a G protein-couple

103 Signaling by protease-activated receptor-1 (PAR1), a G protein-couple

104 tein ALIX regulates lysosomal degradation of protease-activated receptor-1 (PAR1), a GPCR for thrombi

105 d facilitated APC cleavage and activation of protease-activated receptor-1 (PAR1), leading to enhance

106 sition and activates human platelets through protease-activated receptor-1 (PAR1).

107 ar cell recruitment in vivo was dependent on protease-activated receptor-1 activation of the MEK/ERK/

108 of thrombin was attenuated by application of protease-activated receptor-1 and protein kinase C antag

109 The beneficial effects of protease-activated receptor-1 antagonism on limb vascula

110 Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes

111 This study evaluated effects of protease-activated receptor-1 antagonist vorapaxar (Merc

112 elets by alternate mechanisms, including the protease-activated receptor-1 antagonist vorapaxar, have

113 itor leupeptin or two structurally different protease-activated receptor-1 antagonists (SCH79797 and

114 Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagoni

115 ing the thrombin-activatable receptor PAR-1 (protease-activated receptor-1), in Runx1/Cbfb-deleted ML

116 or, low-density lipoprotein-related protein, protease-activated receptor-1, or matrix metalloproteina

117 EGF receptor (EGFR) and a thrombin receptor (protease-activated receptor-1, PAR-1) increases the expr

118 Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for

119 thermore, MMP-1 induced vasoconstriction via protease-activated receptor-1, whose expression was sign

120 mplex in response to signals transduced from protease-activated receptor-1.

121 pression of Card10 mRNA and protein, but not protease-activated receptor-1.

122 is externalized via calcium mobilization and protease-activated receptors-1 and -4, and 48% is contai

123 s of pooled and recombinant human tryptases, protease activated receptor 2 agonist and antagonist pep

124 Protease-activated receptor 2 (PAR(2)), a receptor for i

125 Protease-activated receptor 2 (PAR-2) is activated by se

126 Protease-activated receptor 2 (PAR-2) is expressed in va

127 Protease-activated receptor 2 (PAR-2), a receptor for tr

128 neutrophils, T lymphocytes, mast cells, and protease-activated receptor 2 (PAR-2).

129 odels, we identified the interaction between protease-activated receptor 2 (PAR2) and serine protease

130 A protease-activated receptor 2 (PAR2) antagonist and PAR2

131 lation, and the EPCR-dependent activation of protease-activated receptor 2 (PAR2) by the ternary TF-V

132 Previous studies have revealed that protease-activated receptor 2 (PAR2) contributes signifi

133 which regulates liver TICs through the CTSS/protease-activated receptor 2 (PAR2) loop.

134 The G-protein-coupled protease-activated receptor 2 (PAR2) plays an important

135 Protease-activated receptor 2 (PAR2) signaling and downs

136 d scaffold of coagulation proteases cleaving protease-activated receptor 2 (PAR2) that plays pivotal

137 nzyme B did not kill, but instead stimulated protease-activated receptor 2 (PAR2) to cooperate with I

138 nocytes lacking TRPV3 impair the function of protease-activated receptor 2 (PAR2), resulting in reduc

139 F) conditions induced KLK5 and activated the protease-activated receptor 2 (PAR2), resulting in thymi

140 gulation factor VIIa-dependent activation of protease-activated receptor 2 (PAR2).

141 avage of a G-protein coupled receptor called protease-activated receptor 2 (PAR2).

142 g proinflammatory cytokine secretion through protease-activated receptor 2 (PAR2).

143 like trypsin receptor 1 (F2RL1, also called protease-activated receptor 2 [PAR2]).

144 Protease-activated receptor 2 activates airway apical me

145 We also provide molecular evidence that protease-activated receptor 2 activation followed by PI3

146 Der p1 activates protease-activated receptor 2 and induces the release of

147 nization of the skin could be blocked by the protease-activated receptor 2 antagonist ENMD-1068.

148 regulate PKA activity in cardiomyocytes via protease-activated receptor 2 proteolysis.

149 d to be unaffected, as calcium signaling via protease-activated receptor 2 remained unaltered.

150 Furthermore, we show that protease-activated receptor 2 signaling is involved in m

151 ators and suppressed the activation of EGFR, protease-activated receptor 2, nucleotide-binding domain

152 lammatory mediators, and activation of EGFR, protease-activated receptor 2, nucleotide-binding domain

153 onditions induced kallikrein 5 and activated protease-activated receptor 2, resulting in thymic strom

154 ficantly reduced in STAT6-deficient, but not protease-activated receptor 2-deficient mice.

155 er dysfunction, itch, and dermatitis via the protease-activated receptor 2-thymic stromal lymphopoiet

156 APOE secretion from BALF macrophages through protease-activated receptor 2.

157 nduces A549 IL-8 secretion via activation of protease-activated receptor 2.

158 ydroxytryptamine [5-HT]), histamine, SLIGRL (protease-activated receptors 2/mas-related G-protein-cou

159 her protease activated receptor-1 (PAR-1) or protease activated receptor-2 (PAR-2) on nonhematopoieti

160 sm that was dependent upon the activation of protease activated receptor-2 and adenosine triphosphate

161 tivation of two Galpha(q)-coupled receptors, protease-activated receptor-2 (PAR(2)) and neurokinin-1

162 Proteases that cleave protease-activated receptor-2 (PAR(2)) at Arg(36) downwa

163 We report that legumain (Lgmn) cleaves protease-activated receptor-2 (PAR(2)) in the acidic OSC

164 Protease-activated receptor-2 (PAR(2)) is a G-protein co

165 Protease-activated receptor-2 (PAR(2)) is one of four pr

166 mal activity in acidic environments, cleaves protease-activated receptor-2 (PAR(2)) on neurons to pro

167 stain hyperexcitability and pain by cleaving protease-activated receptor-2 (PAR(2)) on nociceptors th

168 Protease-activated receptor-2 (PAR-2) mediates pro-infla

169 The G protein-coupled receptor protease-activated receptor-2 (PAR-2) plays a key role i

170 rthermore, matriptase elicited signaling via protease-activated receptor-2 (PAR-2), and promoted fibr

171 ombosis and activates cell signaling through protease-activated receptor-2 (PAR-2).

172 in turn cleaved the pericellular substrates protease-activated receptor-2 (PAR2) and pro-urokinase.

173 uch as trypsin and mast cell tryptase cleave protease-activated receptor-2 (PAR2) at R(36) downward a

174 This study sought to evaluate the role of protease-activated receptor-2 (PAR2) in coxsackievirus B

175 Protease-activated receptor-2 (PAR2) is an emerging new

176 at degrades elastic fibers and activates the protease-activated receptor-2 (PAR2) on endothelial cell

177 Protease-activated receptor-2 (PAR2) traffics to lysosom

178 Protease-activated receptor-2 (PAR2), a cell surface rec

179 ta-Tryptase, but not homotetramer, activates protease-activated receptor-2 (PAR2), which is expressed

180 type 2 innate lymphoid cells, which required protease-activated receptor-2 expression.

181 e dependent on subtilisin protease activity, protease-activated receptor-2, IL-33R ST2, and MyD88 sig

182 KK modulates endothelial cell function in a protease-activated receptor-2-dependent manner, leading

183 The mechanism involved epithelial protease-activated receptor-2-dependent production of le

184 In vitro, protease-activated receptor-2-dependent vascular permeab

185 ates nociceptors to induce visceral pain via protease-activated receptor-2.

186 ic nociceptors, which required expression of protease-activated receptor-2.

187 on of beta2-adrenergic receptor (beta2AR) or Protease-activated-receptor-2 (PAR2) results in relief f

188 isms for these contrasting cellular effects, protease activated receptor 3 (PAR3) activation by APC a

189 ptors endothelial protein C receptor (EPCR), protease-activated receptor 3 (PAR3), and macrophage-1 a

190 ed injury depended upon interactions between protease-activated receptor 3 and protease-activated rec

191 hrombin-dependent interactions between human protease-activated receptor 3 and protease-activated rec

192 el, including protease activated receptor-1, protease activated receptor-3, platelet activating facto

193 versible fibrinogen binding in response to a protease activated receptor 4 (PAR4) thrombin receptor a

194 nules, C type lectin receptor-2 (CLEC-2), or protease activated receptor 4 (PAR4).

195 mice lacking the platelet thrombin receptor, protease activated receptor 4 (PAR4; Par4(-/-)), or its

196 sed to arachidonic acid, collagen, U46619 or protease activated receptor 4 activating peptide.

197 P4pal-10 is a protease activated receptor 4-derived pepducin that exhi

198 s platelet and endothelial cell function via protease-activated receptor 4 (PAR-4).

199 novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by devel

200 We analyzed protease-activated receptor 4 (Par4) expression in mouse

201 Protease-activated receptor 4 (PAR4) mediates sustained

202 Here we show that the thrombin receptor protease-activated receptor 4 agonist peptide AYPGKF eli

203 etween rat protease-activated receptor 1 and protease-activated receptor 4 in cultured podocytes.

204 ns between protease-activated receptor 3 and protease-activated receptor 4 in human podocytes, and be

205 nd between protease-activated receptor 1 and protease-activated receptor 4 in rat podocytes.

206 increased activation after administration of protease-activated receptor 4 peptide and convulxin.

207 ncreased platelet responses on activation of protease-activated receptor 4 thrombin receptors noted i

208 Activating protease-activated receptor 4, a platelet receptor for t

209 ing Gbeta1) in murine megakaryocytes reduced protease-activated receptor 4, activating peptide-induce

210 ween human protease-activated receptor 3 and protease-activated receptor 4, and between rat protease-

211 other antiplatelet compounds (antagonists of protease-activated receptor 4, MRS 2179, and clopidogrel

212 Activation with protease-activated receptor 4- activating peptide, the m

213 ur previous study, surface modification with protease-activated receptor 4-activating peptide (PAR4-A

214 Inhibition of protease-activated receptor-4 (PAR-4), but not PAR-2, bl

215 In platelets and other cell types, protease-activated receptor-4 (PAR4) has been shown to d

216 Protease-activated receptor-4 (PAR4) is a G protein-coup

217 ts in blood from mice lacking cathepsin G or protease-activated receptor-4 (PAR4), indicating that ca

218 ect thrombin activation of platelets through protease-activated receptor-4 did not contribute to hepa

219 that suppress excitability via activation of protease-activated receptor-4.

220 This effect is independent of protease-activated receptor activation but requires prot

221 Stimulation of washed human platelets with protease-activated receptor agonists caused translocatio

222 cates to the membrane after stimulation with protease-activated receptor agonists in a Gq-dependent m

223 opportunities for drug development at other protease activated receptors and across GPCRs.

224 ith the endothelial cell protein C receptor, protease-activated receptors, and other receptors to exe

225 Protease-activated receptors are important targets for d

226 f other GPCRs, such as the ADP receptors and protease-activated receptors, can also potentiate CLEC-2

227 n contrast to its activation of conventional protease-activated receptors, cathepsin S-mediated activ

228 gand, coagulation factor VIIa, TF influences protease-activated receptor-dependent tumor cell behavio

229 eceptors such as the Toll-like receptors and protease-activated receptors, endogenous proteins with p

230 ping revealed that rat podocytes express the protease-activated receptor family of coagulation recept

231 Protease-activated receptors have been implicated as the

232 e proteases, serine protease inhibitors, and protease-activated receptors have been intensively inves

233 ad no effect on the Ca(2+) signals evoked by protease-activated receptors, heterologously expressed m

234 Thrombin, via its protease-activated receptors, is postulated to activate

235 bin potently activates platelets through the protease-activated receptor PAR-1.

236 It is now well accepted that protease activated receptor (PAR) 1 and PAR4 have differ

237 The involvement of protease activated receptor (PAR)-2 was evaluated using

238 is was not seen in platelets stimulated by a protease activated receptor (PAR)-4 peptide, which is un

239 progression through cell signaling involving protease activated receptor (PAR)2.

240 induce signalling through activation of the protease activated receptor (PAR)2.

241 atelet aggregation to arachidonic acid, ADP, protease-activated receptor (PAR) 1 activation peptide (

242 Agonism of protease-activated receptor (PAR) 1 by activated protein

243 e the endothelial protein C receptor (EPCR), protease-activated receptor (PAR) 1, and PAR3.

244 which thrombin contributes via activation of protease-activated receptor (PAR) 1.

245 of the collagen glycoprotein VI and thrombin protease-activated receptor (PAR) 1.

246 Protease-activated receptor (PAR) 2 is a G-protein-coupl

247 ain directly activated naive T cells through protease-activated receptor (PAR) 2 to initiate a chemok

248 Protease-activated receptor (PAR) signaling is closely l

249 n of coagulation proteases and activation of protease-activated receptor (PAR)-1 and PAR-2.

250 uman platelets express 2 thrombin receptors: protease-activated receptor (PAR)-1 and PAR4.

251 sent study we investigated the importance of protease-activated receptor (PAR)-2 and its ligand mast

252 In this study, we examined the protease-activated receptor (PAR)-2, a GPCR previously s

253 Protease-activated receptor (PAR)-2, Toll-like receptor

254 following i.d. 5-HT (5-hydroxytryptamine), a protease-activated receptor (PAR)-4 agonist, and an Mrgp

255 lood, Miyakawa et al show that platelets and protease-activated receptor (PAR)-4 contribute to acetam

256 et accumulation were reduced in mice lacking protease-activated receptor (PAR)-4, which mediates thro

257 ssential role in TPO-mediated (i) priming of protease-activated receptor (PAR)-mediated integrin alph

258 botic disorders, we compared the efficacy of protease-activated receptor (PAR)1 and PAR4 in the gener

259 ow provide evidence that C4a is a ligand for protease-activated receptor (PAR)1 and PAR4.

260 Specifically, protease-activated receptors (PAR) 1 and 2, responsive t

261 With the recent interest of protease-activated receptors (PAR) 1 and PAR4 as possibl

262 FXa signalling via activation of protease-activated receptors (PAR) leads to increased in

263 G-protein-coupled receptors (GPCR) known as protease-activated receptors (PAR).

264 We now demonstrate that protease-activated-receptor (PAR) agonists also stimulat

265 synthetic peptides and pepducins to describe protease-activated receptor PAR1 and PAR4 signaling.

266 The case of the protease-activated receptor PAR1 is particularly relevan

267 (m) values for the hydrolysis of fibrinogen, protease-activated receptor PAR1, and protein C that spa

268 The protease-activated receptors (PAR1 and PAR2) are unusual

269 atomic force microscopy (AFM) to image human protease-activated receptors (PAR1) in the functionally

270 y be caused by thrombin acting on astrocytic protease-activated receptors (PAR1) in the hindbrain.

271 GPCRs and other membrane proteins, including protease-activated receptors (PAR1, PAR2, and PAR4), che

272 h as the epithelial sodium channel ENaC, the protease-activated receptor PAR2, the tight junction pro

273 naria exposure appeared to be independent of protease-activated receptor (PAR2) stimulation.

274 ng the proteolytic activity of allergens via protease-activated receptors (PAR2) to initiate inflamma

275 cate that TF signaling via G protein-coupled protease-activated receptors (PAR2, PAR1) additionally d

276 cts appeared to be mediated through specific protease activated receptors (PARs) and sphingosine-1-ph

277 atherosclerosis, presumably mediated through protease activated receptors (PARs).

278 likrein directly activates G protein-coupled protease-activated receptors (PARs) 1 and 2, which posse

279 Here we report that stimulation of protease-activated receptors (PARs) activates YAP/TAZ by

280 Protease-activated receptors (PARs) are a family of G-pr

281 Protease-activated receptors (PARs) are a family of seve

282 Protease-activated receptors (PARs) are G protein-couple

283 Protease-activated receptors (PARs) are G-protein-couple

284 Protease-activated receptors (PARs) are G-protein-couple

285 Endothelial protease-activated receptors (PARs) are potential serine

286 Protease-activated receptors (PARs) can activate HSCs th

287 The nature of protease-activated receptors (PARs) capable of activatin

288 Expression of protease-activated receptors (PARs) mRNA was detected in

289 mation through the proteolytic activation of protease-activated receptors (PARs), fibrinogen, factor

290 Coagulation proteases activate protease-activated receptors (PARs).

291 oprotein Ibalpha (GpIbalpha) and cleavage of protease-activated receptors (PARs).

292 and exerts profibrotic effects by activating protease-activated receptors (PARs).

293 iple physiologically important responses via protease-activated receptors (PARs).

294 we examined the roles of thrombin receptors (protease-activated receptors, PARs) and the ADP receptor

295 Together, our results suggest a role for protease-activated receptor signaling in neural tube clo

296 ulation-activated osteopontin, chemerin, and protease-activated receptor signaling, as well as platel

297 thrombin contributes to podocyte injury in a protease-activated receptor-specific manner during nephr

298 ings showed that activation of astrocytes by protease-activated receptors stimulated interneurons in

299 o-l-arginine methyl ester (100 mumol/L) or a protease-activated receptor type 1 blocker (BMS 200261,

300 otype among an unusual group of GPCRs called protease activated receptors, which self-activate after